Healthy Clinical Trial
Official title:
A Phase 1b, Open-label Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FXR Agonist/Modulator EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients
This is a single centre, open label, randomized, 3 treatment arms, with and without food dosing, Phase 1b pharmacology study to assess the safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Farnesoid X Receptor (FXR) agonist/modulator EYP001a in healthy volunteers and Nonalcoholic Steatohepatitis (NASH) patients.
In total 16 participants (4 healthy volunteers and 12 NASH patients) will be enrolled and
randomly assigned to one of the 3 treatment arms:
- Treatment Arm 1: Dose A once daily morning dose (n=4 NASH patients, n=4 healthy
volunteers)
- Treatment Arm 2: Dose B once daily morning dose (n=4 NASH patients)
- Treatment Arm 3: Dose C twice daily - first morning dose and second dose 3 hours post
first dose (n=4 NASH patients).
Subsequently, all the enrolled participants (both healthy volunteers and NASH patients) will
be randomly assigned to one of the 2 parallel study Groups:
- Group A (n=8, 2 healthy volunteers and 6 NASH patients): This group will include 2 NASH
patients from Treatment Arms 1, 2 and 3 and 2 healthy volunteers from Treatment Arm 1.
Participants in Group A will be dosed in a fasted state on Days 2, 3, 4 and 5 followed
by dosing in fed state on Days 6, 7, 8 and 9.
- Group B (n=8, 2 healthy volunteers and 6 NASH patients): This group will include 2 NASH
patients from Treatment Arms 1, 2 and 3 and 2 healthy volunteers from Treatment Arm 1.
Participants in Group B will be dosed in a fed state on Days 2, 3, 4 and 5 followed by
dosing in fasted state on Days 6, 7, 8 and 9.
The maximum total engagement duration for eligible participants in this study is up to 76
days: 60 days screening, 1-day admission visit and 8 days dosing period (in-patient in
clinical trial unit) and 7 days follow-up.
The participants who are eligible for enrolment will be admitted to the Clinical Trial Unit
on Day 1. The participants will receive EYP001a at the study site by trained personnel per
the schedule of dosing for the study from Day 2 to Day 9 in fed/fasted state depending upon
the study group. Participants will be discharged on the morning (8:00 AM) of Day 10 after
collection of last PK and PD blood samples. Participants will return to the Clinical Trial
Unit on Day 16 for the follow-up visit.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |